Safety in a Phase 1 Randomized, Double-Blinded, Placebo-Controlled Trial Evaluating Two Adenovirus HIV Vaccines in Three Different Geographic Regions

Safety in a Phase 1 Randomized, Double-Blinded, Placebo-Controlled Trial Evaluating Two Adenovirus HIV Vaccines in Three Different Geographic Regions

Background: Homologous and heterologous prime-boost regimens were compared using two adenovirus vectors (Ad26.EnvA. 01 [Ad26] and Ad35-EnvA [Ad35]) in the USA, East Africa and South Africa. This is the first trial using either vector for an HIV preventive vaccine in Africa. Safety data between these...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:AIDS research and human retroviruses 2013-11, Vol.29 (11), p.A-148
Hauptverfasser: Karita, E, Mutua, G, Bekker, L, Gray, G, Page-Shipp, L, Baden, L, Bayingana, R, Nyombayire, J, Anzala, O, Nyasani, D, Roux, S, Mangenya, N, Laher, F, Mambe, M, Innes, C, Mngadi, K, Walsh, S, Johnson, J, Dolin, R, Stevens, G, Grunenberg, N, Barouch, D, Fast, P, Laufer, D
Format: Artikel
Sprache:eng
Schlagworte:
Adenovirus
Human immunodeficiency virus
Retrovirus
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background: Homologous and heterologous prime-boost regimens were compared using two adenovirus vectors (Ad26.EnvA. 01 [Ad26] and Ad35-EnvA [Ad35]) in the USA, East Africa and South Africa. This is the first trial using either vector for an HIV preventive vaccine in Africa. Safety data between these regions were compared.
ISSN:0889-2229